Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10125733 | 0.78 | MAPT (0.70) | GAAALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL5527258 | 0.75 | MAPT (0.74) | GAAALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL5463743 | 0.75 | MAPT (0.77) | GAAALDH1A1KMT2ALMNAMAPT | |
| SCHEMBL15836654 | 0.74 | ALDH1A1 (0.98) | GAAALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL15836650 | 0.74 | ALDH1A1 (0.98) | GAAALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL4070839 | 0.74 | ALDH1A1 (0.84) | GAAALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL5524600 | 0.73 | LMNA (0.62) | GAAALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL5432715 | 0.73 | MAPT (1.00) | GAAALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL3300404 | 0.72 | ALDH1A1 (0.84) | GAAALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL9233597 | 0.72 | ALDH1A1 (0.68) | GAAALDH1A1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | GAA 266/4885GFER 4812/4885ALDH1A1 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.